A rare Ewing sarcoma/peripheral primitive neuroectodermal tumor that affects the central nervous system either as a primary dural neoplasm or by direct extension from adjacent soft tissues or bone.
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding CNS PNET reflects the rarity of the condition, which affects fewer than a small number of individuals worldwide. This has resulted in a lack of systematic clinical studies and comprehensive data collection, making it challenging to establish a clear clinical picture or treatment guidelines. Ongoing research may provide more insights in the future.
To navigate your care for CNS PNET, it is essential to seek a specialist with experience in neuro-oncology, particularly one familiar with rare tumors of the central nervous system. Consider reaching out to major cancer centers or academic institutions that conduct research in this area. While there are currently no identified patient organizations, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, inquire about participation in clinical trials, as these may offer access to cutting-edge therapies.
There are several orphan drugs in development for CNS PNET, including a novel humanized bispecific XmAb T cell recruiting antibody, ANA-conjugated dactunomycin nanoemulsion, dinutuximab beta, padnarsertib, and a small molecule Ewing Sarcoma breakpoint region 1/Friend leukemia virus integration 1 fusion protein inhibitor. Currently, there are 10 active clinical trials investigating these and other potential treatments. For more information, you can explore the trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=central%20nervous%20system%20Ewing%20sarcoma%2Fperipheral%20primitive%20neuroectodermal%20tumor.
Actionable guidance for navigating care for central nervous system Ewing sarcoma/peripheral primitive neuroectodermal tumor
To navigate your care for CNS PNET, it is essential to seek a specialist with experience in neuro-oncology, particularly one familiar with rare tumors of the central nervous system. Consider reaching out to major cancer centers or academic institutions that conduct research in this area. While there are currently no identified patient organizations, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, inquire about participation in clinical trials, as these may offer access to cutting-edge therapies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding CNS PNET reflects the rarity of the condition, which affects fewer than a small number of individuals worldwide. This has resulted in a lack of systematic clinical studies and comprehensive data collection, making it challenging to establish a clear clinical picture or treatment guidelines. Ongoing research may provide more insights in the future.
To navigate your care for CNS PNET, it is essential to seek a specialist with experience in neuro-oncology, particularly one familiar with rare tumors of the central nervous system. Consider reaching out to major cancer centers or academic institutions that conduct research in this area. While there are currently no identified patient organizations, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, inquire about participation in clinical trials, as these may offer access to cutting-edge therapies.
There are several orphan drugs in development for CNS PNET, including a novel humanized bispecific XmAb T cell recruiting antibody, ANA-conjugated dactunomycin nanoemulsion, dinutuximab beta, padnarsertib, and a small molecule Ewing Sarcoma breakpoint region 1/Friend leukemia virus integration 1 fusion protein inhibitor. Currently, there are 10 active clinical trials investigating these and other potential treatments. For more information, you can explore the trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=central%20nervous%20system%20Ewing%20sarcoma%2Fperipheral%20primitive%20neuroectodermal%20tumor.
Actionable guidance for navigating care for central nervous system Ewing sarcoma/peripheral primitive neuroectodermal tumor
To navigate your care for CNS PNET, it is essential to seek a specialist with experience in neuro-oncology, particularly one familiar with rare tumors of the central nervous system. Consider reaching out to major cancer centers or academic institutions that conduct research in this area. While there are currently no identified patient organizations, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, inquire about participation in clinical trials, as these may offer access to cutting-edge therapies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding CNS PNET reflects the rarity of the condition, which affects fewer than a small number of individuals worldwide. This has resulted in a lack of systematic clinical studies and comprehensive data collection, making it challenging to establish a clear clinical picture or treatment guidelines. Ongoing research may provide more insights in the future.
To navigate your care for CNS PNET, it is essential to seek a specialist with experience in neuro-oncology, particularly one familiar with rare tumors of the central nervous system. Consider reaching out to major cancer centers or academic institutions that conduct research in this area. While there are currently no identified patient organizations, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, inquire about participation in clinical trials, as these may offer access to cutting-edge therapies.
There are several orphan drugs in development for CNS PNET, including a novel humanized bispecific XmAb T cell recruiting antibody, ANA-conjugated dactunomycin nanoemulsion, dinutuximab beta, padnarsertib, and a small molecule Ewing Sarcoma breakpoint region 1/Friend leukemia virus integration 1 fusion protein inhibitor. Currently, there are 10 active clinical trials investigating these and other potential treatments. For more information, you can explore the trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=central%20nervous%20system%20Ewing%20sarcoma%2Fperipheral%20primitive%20neuroectodermal%20tumor.
Actionable guidance for navigating care for central nervous system Ewing sarcoma/peripheral primitive neuroectodermal tumor
To navigate your care for CNS PNET, it is essential to seek a specialist with experience in neuro-oncology, particularly one familiar with rare tumors of the central nervous system. Consider reaching out to major cancer centers or academic institutions that conduct research in this area. While there are currently no identified patient organizations, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, inquire about participation in clinical trials, as these may offer access to cutting-edge therapies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.